Tarsus Pharmaceuticals (TARS) – Analysts’ Weekly Ratings Changes

Tarsus Pharmaceuticals (NASDAQ: TARS) recently received a number of ratings updates from brokerages and research firms:

• 2/28/2026 – Tarsus Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/25/2026 – Tarsus Pharmaceuticals was downgraded by Zacks Research from “strong-buy” to “hold”.
• 2/25/2026 – Tarsus Pharmaceuticals had its price target raised by Oppenheimer Holdings, Inc. from $95.00 to $105.00. They now have an “outperform” rating on the stock.
• 2/25/2026 – Tarsus Pharmaceuticals had its price target raised by Guggenheim from $87.00 to $90.00. They now have a “buy” rating on the stock.
• 2/5/2026 – Tarsus Pharmaceuticals had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $68.00 price target on the stock.
• 1/23/2026 – Tarsus Pharmaceuticals was upgraded by Zacks Research from “hold” to “strong-buy”.
• 1/22/2026 – Tarsus Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the transaction, the chief executive officer owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. This trade represents a 0.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Dianne C. Whitfield sold 7,397 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the sale, the insider directly owned 38,958 shares of the company’s stock, valued at $3,120,535.80. The trade was a 15.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 8.97% of the stock is owned by company insiders.

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.